Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 4/2018

01-10-2018 | Original Article

Mutations in context: implications of BRCA testing in diverse populations

Authors: Gabriela E. S. Felix, Yonglan Zheng, Olufunmilayo I. Olopade

Published in: Familial Cancer | Issue 4/2018

Login to get access

Abstract

Cancer is a common non-communicable disease worldwide, although it exhibits differential population trends in incidence and mortality rates. The differences relate to population structure, environmental risk factors as well as health system organization. This article discusses the potential impact of genetic testing on population health, focusing in particular on the mutational spectrum of breast cancer susceptibility genes in diverse populations. We identify the need for improved access to, and increased investment in, comprehensive cancer risk assessment and genetic testing as well as cancer control measures that take into account lifestyle, environmental, and social factors in understudied minority groups.
Literature
1.
WHO (2014) Global status report on noncommunicable diseases 2014. World Health. doi: ISBN 9789241564854
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Petrucelli N, Daly MB, Feldman GL (2013) BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer
13.
14.
Mahfoudh W, Bouaouina N, Ahmed S, Ben et al (2012) Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep 39:1037–1046. doi: 10.​1007/​s11033-011-0829-8 CrossRefPubMed
15.
16.
17.
18.
Shanmughapriya S, Nachiappan V, Natarajaseenivasan K (2013) BRCA1 and BRCA2 mutations in the ovarian cancer population across race and ethnicity: special reference to Asia. Oncology 84:226–232. doi: 10.​1159/​000346593 CrossRefPubMed
19.
Struewing J, Abeliovich D, Peretz T et al (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198–200. doi: 10.​1038/​ng1096-188 CrossRefPubMed
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Santos NPC, Ribeiro-Rodrigues EM, Ribeiro-Dos-Santos AKC et al (2010) Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. Hum Mutat 31:184–190. doi: 10.​1002/​humu.​21159 CrossRefPubMed
31.
32.
33.
34.
35.
36.
37.
38.
39.
Gao Q, Neuhausen S, Cummings S et al (1997) Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet 60:1233–1236PubMedPubMedCentral
40.
Nanda R, Schumm LP, Cummings S et al (2005) Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294:1925–1933. doi: 10.​1001/​jama.​294.​15.​1925 CrossRefPubMed
41.
42.
43.
44.
45.
46.
47.
48.
49.
Hall MJ, Reid JE, Burbidge LA et al (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115:2222–2233. doi: 10.​1002/​cncr.​24200 CrossRefPubMed
50.
Dryja TP, Rapaport JM, Joyce JM, Petersen RA (1986) Molecular detection of deletions involving band q14 of chromosome 13 in retinoblastomas. Proc Natl Acad Sci USA 83:7391–7394CrossRefPubMedPubMedCentral
51.
52.
Fung YK, Murphree AL, T’Ang A et al (1987) Structural evidence for the authenticity of the human retinoblastoma gene. Science 236:1657–1661CrossRefPubMed
53.
Lee WH, Bookstein R, Hong F et al (1987) Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235:1394–1399CrossRefPubMed
54.
Kress M, May E, Cassingena R, May P (1979) Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol 31:472–483PubMedPubMedCentral
55.
Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261–263CrossRefPubMed
56.
Linzer DI, Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43–52CrossRefPubMed
57.
58.
Leppert M, Dobbs M, Scambler P et al (1987) The gene for familial polyposis coli maps to the long arm of chromosome 5. Science 238:1411–1413CrossRefPubMed
59.
60.
Fishel R, Lescoe MK, Rao MR et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027–1038CrossRefPubMed
61.
Leach FS, Nicolaides NC, Papadopoulos N et al (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215–1225CrossRefPubMed
62.
Bronner CE, Baker SM, Morrison PT et al (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258–261. doi: 10.​1038/​368258a0 CrossRefPubMed
63.
Papadopoulos N, Nicolaides NC, Wei YF et al (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263:1625–1629CrossRefPubMed
64.
Cannon-Albright LA, Goldgar DE, Meyer LJ et al (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258:1148–1152CrossRefPubMed
65.
66.
67.
Kamb A, Gruis NA, Weaver-Feldhaus J et al (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440CrossRefPubMed
68.
Berx G, Staes K, van Hengel J et al (1995) Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 26:281–289CrossRefPubMed
69.
Chen LZ, Harris PC, Apostolou S et al (1991) A refined physical map of the long arm of human chromosome 16. Genomics 10:308–312CrossRefPubMed
70.
71.
72.
73.
74.
Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59. doi: 10.​1038/​ng879 CrossRefPubMed
75.
Friedrichsen DM, Malone KE, Doody DR et al (2004) Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women. Breast Cancer Res 6:R629-35. doi: 10.​1186/​bcr933 CrossRefPubMed
76.
77.
Easton DF, Pharoah PDP, Antoniou AC et al. (2015) Gene-panel sequencing and the prediction of breast-cancer risk. 23:2243–2257
78.
79.
80.
81.
82.
Adeniji KA, Huo D, Khramtsov A et al. (2010) Molecular profiles of breast cancer in Ilorin, Nigeria. J Clin Oncol 28:1602CrossRef
83.
Kurebayashi J, Moriya T, Ishida T et al. (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16:S72–S77CrossRefPubMed
84.
85.
Grushko TA, Blackwood MA, Schumm PL et al (2002) Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 62:1481–1488PubMed
86.
87.
Mavaddat N, Barrowdale D, Andrulis IL et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21:134–147. doi: 10.​1158/​1055-9965.​EPI-11-0775 CrossRefPubMed
88.
89.
90.
Fischer C, Kuchenbäcker K, Engel C et al (2013) Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet 50:360–367. doi: 10.​1136/​jmedgenet-2012-101415 CrossRefPubMed
91.
92.
93.
94.
95.
96.
97.
98.
Guindalini Rodrigo Santa Cruz, Huang Yi-Ching, Obeid Elias, Patrick-Miller Linda, Bradbury Angela R., Marion S, Verp, Susan Hong, Kristen Wroblewski, Hiroyuki Abe, Greg S. Karczmar, (2013) Gillian Newstead OIO Breast cancer surveillance in high-risk women with magnetic resonance imaging every 6 months. | 2013 ASCO Annual Meeting | Abstracts | Meeting Library. J Clin Oncol 31, (suppl; abstr 1506). http://​meetinglibrary.​asco.​org/​content/​114172-132. Accessed 30 Dec 2015
99.
100.
Daly B, Olopade OI (2015) A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin 65:221–238. doi: 10.​3322/​caac.​21271 CrossRefPubMed
101.
102.
103.
Reeves MD, Yawitch TM, van der Merwe NC et al (2004) BRCA1 mutations in South African breast and/or ovarian cancer families: Evidence of a novel founder mutation in Afrikaner families. Int J Cancer 110:677–682. doi: 10.​1002/​ijc.​20186 CrossRefPubMed
104.
105.
Pal T, Permuth-Wey J, Holtje T, Sutphen R (2004) BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. Cancer Epidemiol Biomarkers Prev 13:1794–1799PubMed
106.
Solano AR, Aceto GM, Delettieres D et al (2012) BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. Springerplus 1:20. doi: 10.​1186/​2193-1801-1-20 CrossRefPubMedPubMedCentral
107.
108.
109.
110.
Jara L, Ampuero S, Seccia L et al (2002) Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer. Rev médica Chile 130:1113–1123
111.
112.
113.
114.
115.
116.
Levy-Lahad E, Catane R, Eisenberg S et al (1997) Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60:1059–1067PubMedPubMedCentral
117.
118.
119.
Li W-F, Hu Z, Rao N-Y et al (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110:99–109. doi: 10.​1007/​s10549-007-9708-3 CrossRefPubMed
120.
121.
Vaidyanathan K, Lakhotia S, Ravishankar HM et al (2009) BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation. J Biosci 34:415–422CrossRefPubMed
122.
123.
Sekine M, Nagata H, Tsuji S et al (2001) Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population. Clin Cancer Res 7:3144–3150PubMed
124.
125.
126.
Bar-Sade RB, Kruglikova A, Modan B et al (1998) The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet 7:801–805CrossRefPubMed
127.
128.
Wagner TM, Möslinger RA, Muhr D et al (1998) BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J cancer 77:354–360CrossRefPubMed
129.
130.
Peelen T, van Vliet M, Petrij-Bosch A et al (1997) A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60:1041–1049PubMedPubMedCentral
131.
Claes K, Machackova E, De Vos M, et al (1999) Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A>G. Dis Markers 15:69–73CrossRefPubMedPubMedCentral
132.
133.
134.
135.
136.
Stoppa-Lyonnet D, Laurent-Puig P, Essioux L et al (1997) BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 60:1021–1030PubMedPubMedCentral
137.
Van Der Looij M, Szabo C, Besznyak I et al (2000) Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J cancer 86:737–740CrossRef
138.
Thorlacius S, Sigurdsson S, Bjarnadottir H et al (1997) Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60:1079–1084PubMedPubMedCentral
139.
Johannesdottir G, Gudmundsson J, Bergthorsson JT et al (1996) High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res 56:3663–3665PubMed
140.
141.
142.
143.
Heimdal K, Maehle L, Apold J et al (2003) The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur J Cancer 39:2205–2213. doi: 10.​1016/​s0959-8049(03)00548-3 CrossRefPubMed
144.
145.
146.
Machado PM, Brandao RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk breast/ovarian Cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027–2034. doi: 10.​1200/​JCO.​2006.​06.​9443 CrossRefPubMed
147.
Peixoto A, Santos C, Rocha P et al (2009) The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat 114:31–38. doi: 10.​1007/​s10549-008-9978-4 CrossRefPubMed
148.
149.
Pohlreich P, Zikan M, Stribrna J et al (2005) High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 7:R728-36. doi: 10.​1186/​bcr1282 CrossRefPubMed
150.
151.
152.
153.
154.
Bergman A, Einbeigi Z, Olofsson U et al (2001) The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 9:787–793. doi: 10.​1038/​sj.​ejhg.​5200704 CrossRefPubMed
155.
Metadata
Title
Mutations in context: implications of BRCA testing in diverse populations
Authors
Gabriela E. S. Felix
Yonglan Zheng
Olufunmilayo I. Olopade
Publication date
01-10-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0038-2

Other articles of this Issue 4/2018

Familial Cancer 4/2018 Go to the issue

Original Article

Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis

Letter to the Editor

Commentary: PREMM5 threshold of 2.5% is recommended to improve identification of PMS2 carriers

Original Article

Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer

Original Article

Gene expression analysis in peripheral blood cells of patients with hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC): identification of NRF2 pathway activation

Original Article

Feasibility of endoscopic resection using bipolar snare for nonampullary duodenal tumours in familial adenomatous polyposis patients

Original Article

APC mosaicism in a young woman with desmoid type fibromatosis and familial adenomatous polyposis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits